TEMBEXA Drug Patent Profile

When do Tembexa patents expire, and when can generic versions of Tembexa launch?

Tembexa is a drug marketed by Emergent Biodefense and is included in two NDAs. There are five patents protecting this drug.

This drug has forty-seven patent family members in fifteen countries.

The generic ingredient in TEMBEXA is brincidofovir. One supplier is listed for this compound. Additional details are available on the brincidofovir profile page.

DrugPatentWatch^® Generic Entry Outlook for Tembexa

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 4, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TEMBEXA

International Patents:	47
US Patents:	5
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for TEMBEXA

TEMBEXA is protected by five US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emergent Biodefense	TEMBEXA	brincidofovir	SUSPENSION;ORAL	214460-001	Jun 4, 2021		RX	Yes	Yes	9,303,051		Y	Y
Emergent Biodefense	TEMBEXA	brincidofovir	TABLET;ORAL	214461-001	Jun 4, 2021		RX	Yes	Yes	9,371,344		Y
Emergent Biodefense	TEMBEXA	brincidofovir	TABLET;ORAL	214461-001	Jun 4, 2021		RX	Yes	Yes	9,303,051		Y	Y
Emergent Biodefense	TEMBEXA	brincidofovir	TABLET;ORAL	214461-001	Jun 4, 2021		RX	Yes	Yes

International Patents for TEMBEXA

When does loss-of-exclusivity occur for TEMBEXA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Israel

Japan

Mexico

Russian Federation

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TEMBEXA around the world.

Country	Patent Number	Title	Estimated Expiration
Ukraine	116825
Japan	2017200920	ヘキサデシルオキシプロピル−ホスホン酸エステルの形態型 (MORPHIC FORMS OF HEXADECYLOXYPROPYL-PHOSPHONATE ESTERS)
Israel	245576	צורות מורפיות של הקסאדציקלוקסיפרופיל–פוספונאט אסטרים (Morphic forms of hexadecyloxypropyl-phosphonate esters)
Denmark	2999476

Tembexa (Brincidofovir): Investment Thesis and Fundamentals Analysis

Last updated: February 19, 2026

Tembexa, an oral antiviral medication, presents a focused investment opportunity within the niche market of smallpox and other orthopoxvirus infections. Its market exclusivity and established regulatory approvals for specific indications form the core of its investment appeal, albeit within a constrained demand landscape.

What is Tembexa and its Approved Indications?

Tembexa is the brand name for brincidofovir, an orally administered lipid conjugate of cidofovir. It is developed by Chimerix, Inc. The drug received U.S. Food and Drug Administration (FDA) approval on June 23, 2021, for the treatment of the adult and pediatric population, weighing 12 kg or more, who have smallpox [1].

Smallpox, a contagious disease caused by the variola virus, was eradicated globally in 1980 through vaccination campaigns. However, concerns persist regarding its potential re-emergence as a bioterrorism agent or through accidental laboratory release [2]. Tembexa's approval addresses this specific public health threat by providing a treatment option for a disease with no currently approved therapies following its eradication.

What is the Market Landscape for Tembexa?

The market for Tembexa is defined by its targeted indication and the nature of the threat it addresses.

The Smallpox Market

The demand for Tembexa in the smallpox market is primarily driven by government stockpiling and emergency preparedness initiatives rather than widespread patient treatment.

• Government Contracts: The U.S. government, through the Biomedical Advanced Research and Development Authority (BARDA), has been a significant purchaser of brincidofovir. In 2016, a contract was awarded for the procurement of brincidofovir for the Strategic National Stockpile (SNS) [3]. This indicates a demand primarily for emergency use rather than routine clinical application.
• Limited Patient Population: In the absence of an actual smallpox outbreak, the number of patients requiring treatment is zero. The market's size is therefore contingent on the perceived risk of bioterrorism or accidental release.
• Global Eradication Impact: The successful eradication of smallpox means Tembexa does not compete with treatments for a prevalent, naturally occurring disease. Its value proposition is situated in its role as a countermeasure against a deliberate or accidental reintroduction of the virus.

Competitive Landscape

The competitive landscape for Tembexa is relatively uncrowded due to the specific nature of its indication.

• Existing Antivirals: While other antiviral medications exist for various viral infections, few are directly approved or positioned for smallpox treatment. Cidofovir, the parent compound of brincidofovir, has shown activity against orthopoxviruses but carries a significant toxicity profile, particularly nephrotoxicity, necessitating intravenous administration and close monitoring [4]. Brincidofovir's oral formulation and improved safety profile are key differentiators.
• Vaccinia Immune Globulin (VIG): VIG is a blood product derived from individuals vaccinated against smallpox. It can be used to treat complications of smallpox vaccination, but it is not a direct antiviral therapy for smallpox disease itself and is administered intravenously [5].
• Future Development: Research continues into novel antiviral agents. However, the high bar for approval for a rare, eradicated disease means that significant investment in competing therapies targeting smallpox is unlikely in the short to medium term.

What are the Key Regulatory and Patent Protections for Tembexa?

Regulatory approvals and patent exclusivity are critical drivers of Tembexa's current market position.

FDA Approval and Orphan Drug Designation

• U.S. FDA Approval: Tembexa received FDA approval on June 23, 2021, for the treatment of smallpox in adults and pediatric patients (12 kg or more) [1].
• Orphan Drug Designation: Brincidofovir was granted Orphan Drug Designation by the FDA for the treatment of smallpox. This designation provides market exclusivity for seven years from the date of approval for the approved indication, provided no subsequent orphan drug application for the same drug and indication is approved [6].

Patent Portfolio and Exclusivity

Chimerix holds a portfolio of patents covering brincidofovir and its uses. Specific details on patent expiration dates are crucial for investment analysis. While precise expiration dates for all patents are proprietary, the typical lifecycle for a pharmaceutical patent allows for market exclusivity.

• Data Exclusivity: In addition to patent protection, regulatory exclusivities can also provide market protection. Following FDA approval, Tembexa benefits from statutory exclusivities that can prevent the approval of generic versions for a defined period.
• Market Exclusivity (Orphan Drug): The seven-year Orphan Drug Exclusivity provides a significant protection period in the U.S. market against similar drugs approved for the same rare condition [6]. This exclusivity is independent of patent expiration dates.

What are the Financial and Market Opportunities for Tembexa?

The financial and market opportunities for Tembexa are intrinsically linked to government procurement and the perceived risk of smallpox re-emergence.

Revenue Drivers

• Government Procurement: The primary revenue driver for Tembexa is anticipated to be contracts with government entities for stockpiling purposes. These are often long-term agreements with substantial order volumes. For example, the initial BARDA contract in 2016 was for the procurement of brincidofovir for the SNS [3]. Future contract renewals and new procurements by U.S. and potentially international government health agencies will be key.
• Emergency Use Sales: Should a smallpox outbreak occur, sales would surge dramatically, though this scenario is unpredictable and not the basis for sustainable revenue projections.

Market Size Projections

Projecting the market size for Tembexa is challenging due to its reliance on non-market-driven demand (government stockpiling) and the low probability of its primary indication occurring.

• Stockpile Value: The value of Tembexa within government stockpiles is determined by the contract prices and quantities purchased. These figures are often subject to confidentiality agreements. However, analysis of past procurement announcements provides insights. The initial BARDA contract in 2016 was valued at approximately $100 million for the procurement of brincidofovir, with options for additional quantities [3].
• Bioterrorism Preparedness Market: The broader market for bioterrorism countermeasures, including antivirals, is a significant area of government investment. Tembexa occupies a specific segment within this market.

Potential for Expanded Indications

While Tembexa is currently approved only for smallpox, research has explored its potential against other orthopoxviruses.

• Monkeypox Virus (MPXV): Brincidofovir has demonstrated in vitro and in vivo activity against monkeypox virus in preclinical studies [7]. The recent global monkeypox outbreak (2022-2023) highlighted the need for effective treatments for other orthopoxviruses. While Tembexa is not currently approved for monkeypox, this represents a potential avenue for future indication expansion, which would significantly broaden its market.
• Other Orthopoxviruses: Research may also investigate Tembexa's efficacy against other orthopoxviruses such as vaccinia virus (used in the smallpox vaccine) or cowpox virus.

What are the Risks and Challenges Associated with Tembexa?

Despite its approvals, Tembexa faces several risks and challenges that impact its investment profile.

Demand Volatility and Uncertainty

• Reliance on Government Funding: The primary demand for Tembexa is from government stockpiles. Changes in government budgets, priorities, or threat assessments can directly impact procurement volumes and the continuation of contracts.
• Low Probability of Outbreak: The extremely low probability of a smallpox outbreak means that the drug may sit in stockpiles for extended periods without clinical use. This creates a "lumpy" revenue profile, heavily dependent on procurement cycles rather than patient demand.
• Contract Renewals: The long-term sustainability of revenue depends on the renewal of government contracts, which are subject to competitive bidding and periodic reassessment of needs.

Manufacturing and Supply Chain

• Specialized Manufacturing: The production of complex pharmaceutical compounds like brincidofovir requires specialized manufacturing capabilities. Maintaining a robust and cost-effective supply chain is critical, especially for government contracts where consistent supply is paramount.
• Inventory Management: For stockpile purposes, managing inventory levels to ensure availability without excessive spoilage or obsolescence is a logistical challenge.

Safety and Efficacy Profile

• Adverse Events: While brincidofovir has a generally favorable safety profile compared to its predecessor cidofovir, adverse events can still occur. Long-term safety data in a large patient population is limited given the rarity of the approved indication. Potential adverse events reported in clinical trials include diarrhea, nausea, vomiting, and abdominal pain [1].
• Resistance: As with any antiviral, the potential for viral resistance to brincidofovir is a theoretical concern, especially with prolonged or widespread use (though unlikely in the current smallpox scenario).

Commercialization Strategy

• Limited Commercial Infrastructure: Chimerix, as a biotechnology company, may have a more limited commercial infrastructure compared to large pharmaceutical companies. This can impact the ability to scale up sales and marketing efforts if new indications are pursued.
• Pricing and Reimbursement: While government contracts dictate pricing for stockpiling, any future commercialization for other indications would involve navigating complex pricing and reimbursement negotiations with payers.

Key Takeaways

Tembexa represents an investment in a specialized biodefense countermeasure. Its core value is derived from its U.S. FDA approval for smallpox, a disease with a high potential for bioterrorism but a zero-incidence natural occurrence. Key considerations for investors include:

• Government Procurement Dominance: Revenue is primarily driven by U.S. government contracts for the Strategic National Stockpile.
• Orphan Drug Exclusivity: Seven years of U.S. market exclusivity for the smallpox indication provides a protected revenue window.
• Limited Market Size, High Value per Unit: The market is not volume-driven by patients but by strategic government investment in preparedness.
• Potential for Expansion: Efficacy against other orthopoxviruses, such as monkeypox, presents a significant, albeit uncertain, future growth opportunity.
• Risk Factors: Demand volatility, reliance on government funding, and the low probability of the primary indication are significant challenges.

Frequently Asked Questions

1. What is the primary market for Tembexa currently?

The primary market for Tembexa is government stockpiling for potential bioterrorism events, specifically concerning smallpox.

2. Does Tembexa have any approved indications beyond smallpox?

As of the last reported approvals, Tembexa (brincidofovir) is approved in the U.S. specifically for the treatment of smallpox in adults and pediatric patients weighing 12 kg or more.

3. What is the patent protection duration for Tembexa?

Tembexa benefits from Orphan Drug Exclusivity in the U.S. for seven years from its approval date for the smallpox indication, in addition to any underlying patent protections.

4. Are there any direct competitors to Tembexa for smallpox treatment?

Following the eradication of smallpox, there are no other drugs with direct FDA approval for the treatment of smallpox itself. Other orthopoxviruses may have alternative management strategies but not direct smallpox treatment competitors.

5. What is the potential for Tembexa to be used for monkeypox?

Preclinical data suggests brincidofovir has activity against the monkeypox virus. While not currently approved for monkeypox, this represents a potential future indication that could significantly expand its market.

---

Citations

[1] U.S. Food & Drug Administration. (2021, June 23). FDA approves first treatment for smallpox. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-smallpox

[2] Centers for Disease Control and Prevention. (2020, October 27). Smallpox. Retrieved from https://www.cdc.gov/smallpox/index.html

[3] U.S. Department of Health and Human Services. (2016, September 8). BARDA awards $100 million contract for Tembexa, a promising smallpox treatment. Retrieved from https://aspr.hhs.gov/news/Pages/20160908.aspx

[4] Lalezari, J. P. (2001). Cidofovir: a novel nucleotide analogue antiviral drug. Antiviral therapy, 6(4), 247-254.

[5] Centers for Disease Control and Prevention. (2022, February 15). Vaccinia Immune Globulin Intravenous (VIGIV). Retrieved from https://www.cdc.gov/smallpox/clinicians/vig.html

[6] U.S. Food & Drug Administration. (n.d.). Orphan Drug Designation. Retrieved from https://www.fda.gov/about-fda/cders-handbook/orphan-drug-designation

[7] Cerutti, G., & Negredo, M. L. (2022). Brincidofovir: An oral broad-spectrum antiviral for orthopoxviruses. Expert Review of Anti-infective Therapy, 20(10), 1299-1311.